Olema Pharmaceuticals Inc (OLMA) - Total Assets
Based on the latest financial reports, Olema Pharmaceuticals Inc (OLMA) holds total assets worth $530.64 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See OLMA stock price and chart for real-time trading data and today's change.
Olema Pharmaceuticals Inc - Total Assets Trend (2018–2025)
This chart illustrates how Olema Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Olema Pharmaceuticals Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Olema Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Olema Pharmaceuticals Inc's total assets of $530.64 Million consist of 96.6% current assets and 3.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.1% |
| Accounts Receivable | $4.06 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Olema Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Olema Pharmaceuticals Inc (OLMA) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Olema Pharmaceuticals Inc's current assets represent 96.6% of total assets in 2025, a decrease from 99.1% in 2018.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2025, down from 96.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Olema Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Olema Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $35.32 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $1.15 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Olema Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.88 | 15.22 | 39.39 |
| Quick Ratio | 10.88 | 15.22 | 39.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $466.06 Million | $370.60 Million | $312.71 Million |
Olema Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Olema Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.94 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | 18.3% |
| Total Assets | $533.43 Million |
| Market Capitalization | $900.55 Million USD |
Valuation Analysis
Above Book Valuation: The market values Olema Pharmaceuticals Inc's assets above their book value (1.69x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Olema Pharmaceuticals Inc's assets grew by 18.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Olema Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Olema Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $533.43 Million | +18.28% |
| 2024-12-31 | $450.98 Million | +62.84% |
| 2023-12-31 | $276.94 Million | +28.43% |
| 2022-12-31 | $215.65 Million | -27.13% |
| 2021-12-31 | $295.94 Million | -13.65% |
| 2020-12-31 | $342.72 Million | +259537.88% |
| 2019-12-31 | $132.00K | -95.96% |
| 2018-12-31 | $3.27 Million | -- |
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive,… Read more